company background image
A096

SeegeneKOSDAQ:A096530 Stock Report

Market Cap

₩3.9t

7D

35.1%

1Y

-21.7%

Updated

29 Nov, 2021

Data

Company Financials +
A096530 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends3/6

A096530 Stock Overview

Seegene, Inc. manufactures and sells molecular diagnostics products worldwide.

Seegene Competitors

Siemens

XTRA:SIE

€115.4b

Siemens Healthineers

XTRA:SHL

€72.3b

Hologic

NasdaqGS:HOLX

US$19.1b

bioMérieux

ENXTPA:BIM

€15.1b

Price History & Performance

Summary of all time highs, changes and price drops for Seegene
Historical stock prices
Current Share Price₩75,000.00
52 Week High₩116,400.00
52 Week Low₩48,200.00
Beta-1.66
1 Month Change40.98%
3 Month Change12.11%
1 Year Change-21.67%
3 Year Change742.70%
5 Year Change356.62%
Change since IPO1,682.88%

Recent News & Updates

Shareholder Returns

A096530KR BiotechsKR Market
7D35.1%4.5%-2.9%
1Y-21.7%-26.3%8.3%

Return vs Industry: A096530 exceeded the KR Biotechs industry which returned -24.4% over the past year.

Return vs Market: A096530 underperformed the KR Market which returned 9.7% over the past year.

Price Volatility

Is A096530's price volatile compared to industry and market?
A096530 volatility
A096530 Average Weekly Movement9.0%
Biotechs Industry Average Movement7.3%
Market Average Movement6.0%
10% most volatile stocks in KR Market11.4%
10% least volatile stocks in KR Market3.4%

Stable Share Price: A096530 is more volatile than 75% of KR stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: A096530's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
2000744Jong-Youn Cheonhttps://www.seegene.com

Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection products; drug resistance products; Magicplex sepsis real-time test for the detection and identification of sepsis causing pathogens; and meningitis detection products. The company also provides other products for the detection of six SNPs in factor II, factor V, and MTHFR genes; BRAF mutation characteristic for papillary thyroid carcinoma from samples of thyroid tissue, fine needle aspiration biopsy, H&E slides, and paraffin-embedded tissues; Apolipoprotein E genotypes; and BCR/ABL fusion gene from blood and whole bone marrow.

Seegene Fundamentals Summary

How do Seegene's earnings and revenue compare to its market cap?
A096530 fundamental statistics
Market Cap₩3.88t
Earnings (TTM)₩559.36b
Revenue (TTM)₩1.40t

6.9x

P/E Ratio

2.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A096530 income statement (TTM)
Revenue₩1.40t
Cost of Revenue₩368.42b
Gross Profit₩1.03t
Expenses₩474.75b
Earnings₩559.36b

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)10.80k
Gross Margin73.73%
Net Profit Margin39.88%
Debt/Equity Ratio9.1%

How did A096530 perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

7%

Payout Ratio

Valuation

Is Seegene undervalued compared to its fair value and its price relative to the market?

6.94x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: A096530 (₩75000) is trading above our estimate of fair value (₩32979.7)

Significantly Below Fair Value: A096530 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: A096530 is good value based on its PE Ratio (6.9x) compared to the KR Biotechs industry average (34.4x).

PE vs Market: A096530 is good value based on its PE Ratio (6.9x) compared to the KR market (15.4x).


Price to Earnings Growth Ratio

PEG Ratio: A096530's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: A096530 is good value based on its PB Ratio (4.2x) compared to the KR Biotechs industry average (4.5x).


Future Growth

How is Seegene forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-51.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: A096530's earnings are forecast to decline over the next 3 years (-51.4% per year).

Earnings vs Market: A096530's earnings are forecast to decline over the next 3 years (-51.4% per year).

High Growth Earnings: A096530's earnings are forecast to decline over the next 3 years.

Revenue vs Market: A096530's revenue is expected to decline over the next 3 years (-31.8% per year).

High Growth Revenue: A096530's revenue is forecast to decline over the next 3 years (-31.8% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: A096530's Return on Equity is forecast to be low in 3 years time (13%).


Past Performance

How has Seegene performed over the past 5 years?

82.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: A096530 has a high level of non-cash earnings.

Growing Profit Margin: A096530's current net profit margins (39.9%) are lower than last year (44.8%).


Past Earnings Growth Analysis

Earnings Trend: A096530's earnings have grown significantly by 82% per year over the past 5 years.

Accelerating Growth: A096530's earnings growth over the past year (74%) is below its 5-year average (82% per year).

Earnings vs Industry: A096530 earnings growth over the past year (74%) exceeded the Biotechs industry 59.8%.


Return on Equity

High ROE: A096530's Return on Equity (60.1%) is considered outstanding.


Financial Health

How is Seegene's financial position?


Financial Position Analysis

Short Term Liabilities: A096530's short term assets (₩903.1B) exceed its short term liabilities (₩260.0B).

Long Term Liabilities: A096530's short term assets (₩903.1B) exceed its long term liabilities (₩77.6B).


Debt to Equity History and Analysis

Debt Level: A096530 has more cash than its total debt.

Reducing Debt: A096530's debt to equity ratio has reduced from 35.2% to 9.1% over the past 5 years.

Debt Coverage: A096530's debt is well covered by operating cash flow (447.8%).

Interest Coverage: A096530's interest payments on its debt are well covered by EBIT (328.6x coverage).


Balance Sheet


Dividend

What is Seegene current dividend yield, its reliability and sustainability?

1.07%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: A096530's dividend (1.07%) is higher than the bottom 25% of dividend payers in the KR market (0.78%).

High Dividend: A096530's dividend (1.07%) is low compared to the top 25% of dividend payers in the KR market (2.44%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, A096530 has been paying a dividend for less than 10 years.

Growing Dividend: A096530's dividend payments have increased, but the company has only paid a dividend for 2 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (7%), A096530's dividend payments are thoroughly covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: A096530's dividends in 3 years are forecast to be well covered by earnings (22.1% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Jong-Youn Cheon (64 yo)

no data

Tenure

Dr. Jong-Youn Cheon founded Seegene, Inc. in 2000 and serves as its Chief Executive Officer and Chief Technology Officer. Dr. Cheon serves as Director at Seegene, Inc.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Seegene, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Seegene, Inc.
  • Ticker: A096530
  • Exchange: KOSDAQ
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₩3.885t
  • Shares outstanding: 51.80m
  • Website: https://www.seegene.com

Number of Employees


Location

  • Seegene, Inc.
  • Taewon Building
  • 91 Ogeum-ro
  • Seoul
  • 5548
  • South Korea

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/29 15:46
End of Day Share Price2021/11/29 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.